

Memo

To: AML Reference Laboratory Clients
From: Allina Medical Laboratories, Reference Laboratory Services
Date: January 28, 2009
Re: AFP Triple Screen Testing Being Discontinued

Genzyme Genetics has shared that effective February 28, 2009 they will no longer offer the **AFP Triple Screen (6770/AF3)** maternal screening test. According to Genzyme's communication, research and professional society guidelines no longer include stand alone triple screen marker tests as part of reasonable standard of care for patients.

The **Maternal Quad Screen (4343/4SB)** is the recommended replacement test as it provides a higher detection rate for aneuploidy and neural tube defects.

Test Name: **MATERNAL QUAD SCREEN**
Test Number: 4343/4SB
Collect: 3.0 ml Serum
Container: Serum Separator Tube (SST)
Processing: Spin
Transport/Stability: Refrigerated
Alternate Names: Quadruple Marker Test, AFP4, Genzyme Quad Screen
Performing Lab: Genzyme Genetics (325)
Days Set Up: Daily
Expected TAT: 2 - 3 Days
Ref. Ranges: See Report
**Collection/
Processing Details:** Prefer collect in 8.5 ml SST; Please completely answer all questions on form or in Excellian. Ultra sound is preferred dating method. Testing includes: Biochemical quantitation of AFP, HCG, Estriol, Inhibin. Optimum testing dates are 16.0 weeks to 18.0 weeks but testing is valid from 15 weeks 0 days to 21 weeks 6 days.
Method: Multiple
CPT Codes: 82105-90; 82677-90; 84702-90; 86336-90